EP1613590A2 — 4-(3,4-disubstituted phenyl)-pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
Assigned to F Hoffmann La Roche AG · Expires 2006-01-11 · 20y expired
What this patent protects
Selective PDE4 inhibition is achieved by 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds exhibit improved PDR4, inhibition as compared to compounds like rolipram and show selectivity with regard to inhibition of other classes of PDEs. The compounds of the present …
USPTO Abstract
Selective PDE4 inhibition is achieved by 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds exhibit improved PDR4, inhibition as compared to compounds like rolipram and show selectivity with regard to inhibition of other classes of PDEs. The compounds of the present invention are of formula (I); wherein R1, R2, and R3 are as defined herein.
Drugs covered by this patent
- Briviact (BRIVARACETAM) · UCB
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.